Twist Bioscience Corp. (TWST) officer Finn Patrick John reported a proposed sale of 2,245 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $302,153.21 and an approximate sale date of October 23, 2026. The shares are listed as restricted stock vesting on October 22, 2026; the notice says the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Twist Bioscience Corp (TWST) Chief Financial Officer Adam Laponis sold 2,462 shares of common stock on October 9, 2026, at $156.3049 per share; his directly held position following the sale was 98,114 shares. The shares were sold as required by the issuer’s equity incentive plans to fund tax withholding obligations connected with vesting of Restricted Stock Units. The transaction was not discretionary, and no Rule 10b5-1 plan is reported.
Twist Bioscience Corp (TWST) is the issuer named in a Rule 144 notice by officer Adam Laponis for a proposed sale of 2,462 common shares, with an aggregate market value of $384,822.66. The shares are listed as acquired through restricted stock vesting on October 8, 2026. The remarks state that the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Twist Bioscience Corp (TWST) Chief Executive Officer Emily M. Leproust reported direct sales of 4,548 common shares on October 5, 2026, across eight entries. The entries list weighted-average sale prices from $200.4379 to $207.4556 per share; the sales were made under a Rule 10b5-1 trading plan adopted June 15, 2026. She also reported employee stock options covering 131,290 common shares at a $23.33 exercise price, expiring October 23, 2029, and options covering 64,950 shares at $67.85, expiring August 31, 2030.
Twist Bioscience Corp officer and director Emily M. Leproust reported a proposed sale of 4,548 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $919,373.72 and an approximate sale date of October 5, 2026. The notice also lists prior common-share sales by Leproust, including 356,546 shares sold on September 17, 2026, with a reported value of $56,330,878.38.
Twist Bioscience Corp (TWST) Chief Financial Officer Adam Laponis reported selling 8,057 shares on October 2, 2026, at $188.8840 per share. The shares were required to be sold to cover tax withholding obligations tied to restricted stock unit vesting under the issuer’s equity-plan election; the footnote says the sale was not discretionary. Laponis directly held 100,576 shares after the sale. No Rule 10b5-1 plan is reported.
Twist Bioscience Corp (TWST) reports that SVP of Human Resources Paula Green sold 10,088 shares of common stock on October 2, 2026, at $188.884 per share. Her direct holdings afterward were 106,632 shares. The footnote ties the sale to tax withholding obligations connected with restricted stock unit vesting under the issuer's equity incentive plans.
Twist Bioscience Corp (TWST) President and COO Patrick John Finn reported a sale of 25,714 common shares on October 2, 2026, at $188.8840 per share, leaving him with 185,088 shares. The shares were required to be sold to cover tax withholding on vesting Restricted Stock Units under the issuer’s equity plans; the footnote says these were not discretionary trades. No Rule 10b5-1 plan is reported.
Twist Bioscience Corp (TWST) reported two direct common-stock sales by Chief Executive Officer Emily M. Leproust: 655 shares on October 1, 2026, at $200.0000 per share under a Rule 10b5-1 plan adopted June 15, 2026; and 45,736 shares on October 2, 2026, at $188.8840 per share to cover tax withholding from Restricted Stock Unit vesting. The latter sale was mandated under the issuer’s equity incentive plans and was not discretionary. She also reported options covering 131,290 common shares at a $23.3300 exercise price, expiring October 23, 2029, and 64,950 common shares at a $67.8500 exercise price, expiring August 31, 2030.
Twist Bioscience Corp (TWST) Senior Vice President, Chief Legal Officer and Corporate Secretary Dennis Cho sold 9,514 shares of common stock on October 2, 2026, at $188.8840 per share, leaving 63,789 shares held directly. The shares were sold to cover tax withholding obligations tied to Restricted Stock Unit vesting; the issuer's equity-plan election mandated the sale, which the footnote says was not discretionary. No Rule 10b5-1 plan is reported.